CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T(SCM) 的构建：具有 super clutch 的 CAR-T
英文原题：Generation of CAR-T(SCM): CAR-T with super clutch.
查看英文原题
Generation of CAR-T(SCM): CAR-T with super clutch.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 疗法已在血液系统恶性肿瘤中证明有效，如今正拓展至实体瘤领域。CAR-T 疗法的主要障碍之一是 T 细胞耗竭，通常由体内持续接触抗原或体外制造过程中的 T 细胞终末分化所致。干细胞样记忆 T 细胞（TSCM）处于初始 T 细胞向下游记忆和效应阶段分化的起始且关键环节。研究人员希望在制造过程中将 CAR-T 细胞维持于 TSCM 阶段，因为 CAR-T 产品中 TSCM 的比例与更好的治疗反应密切相关。本文回顾了近期促进 CAR-TSCM 生成的策略，涉及起始细胞来源、制造流程、CAR 组装、转录因子及代谢调节等方面。
展开英文摘要原文
CAR-T therapy has demonstrated effectiveness in hematological malignancies and is now striding into solid tumor areas. One of the main roadblocks of CAR-T therapy is T cell exhaustion normally aroused by T cell terminal differentiation due to persistent contact with antigen in vivo or in vitro manufacturing process.
T SCM positions as the first, and pivotal step of na ve T cell differentiation to downstream memory and effector stages. Researchers highly seek to restrain CAR-T cells at the T SCM stage during manufacture as T SCM percentage in CAR-T products is strongly associated with better treatment response.
We reviewed the recent strategies regarding CAR-T SCM generation from aspects of starting source, manufacturing process, CAR assembly, transcription factor and metabolism regulation, etc.
论文信息
- 作者
- Hu J、Liu X
- 第一作者单位
- Department of Laboratory Medicine, Gongli Hospital, No. 219, Miaopu Road, Pudong, Shanghai, 200135, China. Electronic address: hjh7677@sina.com.China
- 通讯作者单位
- TriArm Therapeutics Inc, Building 5, Niudun Road, Pudong New District, Shanghai, 201203, China. Electronic address: xiang.liu@triarmbio.com.China
- 文献类型
- 综述
- 期刊
- International immunopharmacology2024 Jul 30
- 原文标识
- PubMed 38833844 · DOI 10.1016/j.intimp.2024.112379